Skip to main content

Table 1 Baseline characteristics* for the entire study cohort and by vertebral fracture status

From: Longitudinal analysis of vertebral fracture and BMD in a Canadian cohort of adult cystic fibrosis patients

   Overall
n = 49
Nonfracture Group
n = 41
Fracture Groupa
n = 8
p-value
  Valid n, Nonfracture/Fracture     
Male gender, % 41/8 42.9 39.0 62.5 0.263
Age, years 41/8 25.2 (9.4) 23.8 (8.7) 32.7 (10.3) 0.024
Weight, kg      
   males 16/5 59.5 (9.2) 56.1 (7.4) 70.4 (5.3) 0.003
   females 25/3 57.4 (16.4) 57.3 (17.5) 58.0 (11.5) 0.726
Height, cm, 41/8 166.8 (7.9) 166.1 (7.7) 170.3 (8.9) 0.175
BMI, kg/m2      
   males 16/5 19.8 (2.8) 18.9 (2.2) 22.8 (2.4) 0.004
   females 25/3 21.7 (5.1) 21.7 (5.3) 22.3 (3.7) 0.726
FEV1 39/8 2.2 (0.9) 2.2 (0.9) 2.5 (0.7) 0.202
FVC 39/8 3.1 (0.9) 3.0 (0.9) 3.4 (0.9) 0.098
Hemoglobin g/L 38/7 139.2 (14.8) 138.1 (14.6) 144.9 (15.2) 0.301
Creatinine, umol/L 34/7 66.8 (17.4) 64.8 (18.1) 76.0 (10.0) 0.045
Calcium, mmol/L 34/5 2.3 (0.1) 2.3 (0.1) 2.3 (0.1) 0.657
Albumin, g/L 37/8 39.7 (3.7) 39.8 (3.9) 39.3 (2.5) 0.550
25-hydroxyvitamin D, nmol/L 26/4 61.9 (28.8) 61.5 (31.0) 64.6 (5.4) 0.617
Parathyroid hormone, pg/ml 17/4 28.0 (17.7) 24.8 (18.0) 41.5 (6.7) 0.120
Phosphate, mmol/L 32/5 1.2 (0.2) 1.2 (0.2) 1.3 (0.1) 0.813
Alkaline Phosphatase, U/L 37/8 121.8 (91.4) 116.6 (89.7) 146.1 (101.5) 0.082
Alanine Aminotransferase, IU/L 36/8 32.5 (29.1) 29.6 (22.0) 45.6 (50.5) 0.560
g-glutamyltransferase, U/L 37/7 31.2 (51.8) 26.7 (39.9) 55.1 (94.2) 0.297
Inhaled Steroids, % yes 41/8 55.1 51.2 75.0 0.269
Vitamin D (ADEK), % yes 41/8 55.1 53.7 62.5a 0.715
  1. Data expressed as mean (SD) or proportion.
  2. *Data was abstracted within 9-months of baseline radiograph.
  3. p < 0.05
  4. aFractures present at baseline (prevalent fractures)
  5. BMI, body mass index; FEV1, Forced Expiratory Volume in 1 second; FVC, Forced Vital Capacity